Manana Elia, M.D.
- Medical Oncology
- Breast Cancer
- Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research
Medical oncologist Manana Elia, M.D., who specializes in treating breast cancer, sees her role as working to provide the best possible outcome for each of her patients without major disruption to their lives.
Dr. Elia joined City of Hope in 2023 with more than 20 years’ worth of experience serving cancer patients. Most recently, she was an assistant professor of medical oncology at the University of Kansas Medical Center, where she was recognized twice with institutional awards for leading clinical trials in the community. Before that, she served as a physician partner in oncology/hematology at U.S. Oncology’s Kansas City Cancer Center in Kansas and as an assistant professor of internal medicine and a staff physician at Tbilisi State Medical University Hospital in the nation of Georgia.
Away from the clinic, Dr. Elia likes to read, play piano and travel.
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
American Board of Internal Medicine, Medical Oncology 2002 - 2012
American Board of Internal Medicine, Hematology 2002
American Board of Internal Medicine 1999
1982, M.D., Tbilisi State Medical University, Tbilisi, Georgia
2000-2002, Fellowship, Hematology & Oncology, University of Kansas Medical Center, Kansas City, Kansas
1999-2000, Fellowship, Hematology & Oncology, Emory University, Atlanta, Georgia
1996-1999, Residency, Internal Medicine, Emory University, Atlanta, Georgia
1982-1984 Internship, Tbilisi State Medical University, Tbilisi, Georgia
2023-present, Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California
2011-2022, Assistant Professor, Medical Oncology, University of Kansas Medical Center, Kansas City, Kansas
2011-2002, Physician Partner, Hematology-Oncology, Kansas City Cancer Center, Kansas City, Kansas
Awards & Memberships
Director’s Award, University of Kansas Medical Center – Clinical Trials in Community Setting, 2018
Director’s Award, University of Kansas Medical Center – Clinical Trials in Community Setting, 2017
Publications
- Sharma P, Stecklein S, Yoder R, Staley J, Schwensen K, O’Dea A, Nye L, Elia M, Satelli D, Crane G, Madan R, O’Neil M, Wagner J, Larson K, Balanoff C, Phadnis M, Godwin A, Salgado R, Khan Q, O’Shaughnessy J. Clinical and biomarker results of neoadjuvant phase 2 study of pembrolizumab and carboplatin plus docetaxel in triple negative breast cancer (TNBC) (NeoPACT). Oral presentation. ASCO 2022.
- Sharma P, Kimler B, O’Dea A, Nye L, Wang Y, Yoder R, Staley J, Prochaska L, Wagner J, Amin A, Larson K, Balanoff C, Elia M, Crane G, Madhusudhana S, Hoffman M, Sheehan M, Rodriguez R, Finke K, Shah R, Satelli D, Shrestha A, Beck L, McKittrick R, Pluenneke R, Raja V, Beeki V, Corum L, Heldstab J, LaFaver S, Prager M, Phadnis M, Mudaranthakam D, Jensen R, Godwin A, Salgado R, Mehta K, Khan Q. Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP). Clin Cancer Res. 2021 Feb 15;27(4):975-982. doi: 10.1158/1078-0432.CCR-20-3646. PMID: 33208340.
- Sharma P, Abramson V, O’Dea A, Nye L, Mayer I, Pathak H, Hoffman M, Stecklein S, Elia M, Lewis S, Scott J, De Jong J, Wang Y, Yoder R, Schwensen K, Finke K, Heldstab J, LaFaver S, Williamson S, Phadnis M, Reed G, Kimler B, Khan Q, Godwin A. Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer. Clin Cancer Res. 2021 Jul 15;27(14):3896-3904. doi: 10.1158/1078-0432.CCR-20-4879. PMID: 33602685.
- Elia M, Kimler b, staley J, Schwensen K, Wang Y, Finke K, O’Dea A, Nye L, Crane G, McKittrick R, Pluenneke R, Madhusudhana S, Beck L, Rodricuez R, Shrestha C, Marsico M, Godwin A, Khan Q, Sharma P. Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2 negative breast cancer. Poster. Mays Cancer Center, AACR, Baylor College of Medicine, December 2020.
- Khan Q, O’Dea A, bardia A, Kalinsjy K, Wisinski K, O’Reegan R, Yuan Y, Ma C, Jahanzeb M, Trivedi M, Spring L, Makhoul I, Wagner J, Winblad O, Amin A, Blau S, Crane G, Elia M, Hard M, Sharma P. Letrozole plus ribociclib compared to letrozole plus placebo as neo-adjuvant therapy for ER positive early breast cancer. Oral presentation. AACR, April 2020.
- Sharma P, Abramson V, O’Dea A, Pathak H, Pesetto Z, Wang Y, Finke K, Hoffman M, Elia M, Lewis S, Scott J, De Jong J, Urban J, Heldstab S, Lafaver S, Williamson S, Reed G, Kimler B, Khan Q, Godwin A. Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.2018. 15 Supplement ed., vol. 36, pp.1018.
- Shah R, Wang Y, Finke K, Yoder R, O’Dea A, Nye L, Madhusudhana S, Hoffman M, Elia M, Crane G, Klemp J, Khan Q, Kimler P, Sharma P. Comparison of outcomes for AJCC 8th anatomic and prognostic staging in contemporary triple negative breast cancer (TNBC) multisite registry. 2018. 15 Supplement ed., vol. 36, pp. 555.
- Prochaska L, Godwin A, Kimler B, Lehn C, Klemp J, O’Dea A, Elia M, Hoffman M, Crane G, McKittrick R, Sheehan M, Graff S, Madhusudhana S, Khan Q, Jensen R, Sharma P. Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer.2017. 4 Supplement ed., vol 77, pp, P5-16-02.
- Sharma P, Klemp J, Kimler B, Mahnken J, Geier L, Khan Q, Elia M, Connor C, McGinness M, Mammen J, Wagner J, Ward C, Ranallo L, Knight C, Stecklein S, Jensen R, Fabian C, Godwin A. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry:implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014 Jun;145(3):707-14. doi: 10.1007/s10549-014-2980-0. PMID: 24807107.